心力衰竭中的β阻塞疗法:科学综述
JoAnne Micale Foody1, Michael H Farrell, Harlan M Krumholz
1Yale University School of Medicine, New Haven, CT 06520-8025, USA.
JAMA
|February 20, 2002
概括
β抑制剂显著降低心力衰竭患者的死亡率和住院病例. 这种类型的药物现在是治疗静缩功能障碍的基石,改善了患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 心力衰竭的管理已经发生了显著的进化,随着对静脉缩功能障碍改善的治疗策略的范式转变.
- 贝塔抑制剂,最初是谨慎的,现在被广泛研究,并证明有效改善心力衰竭的结果.
研究的目的:
- 建立在心力衰竭治疗中使用β抑制剂的科学理由.
- 审查支持使用β抑制剂改善心力衰竭患者临床结果的证据.
主要方法:
- 对大型,英语随机对照试验的系统审查,重点关注β阻塞剂在心力衰竭中的死亡益处.
- 包含基础科学研究,以阐明贝塔抑制剂在心力衰竭中的生理机制.
- 对心力衰竭管理中的β阻断剂建议的当前临床指南的评估.
主要成果:
- 美国有三种β-阻断剂 (比索普罗罗尔,卡维迪罗尔,梅托普罗罗尔),其中卡维迪罗尔和梅托普罗罗尔有FDA对心力衰竭的指示.
- 与安慰剂相比,在心力衰竭 (II-III类) 患者中,β阻塞疗法显示死亡率持续降低30%,住院病例减少40%.
结论:
- 根据涉及超过10,000名参与者的试验,β-阻断剂已被证明可以降低II-IV类心力衰竭患者的发病率和死亡率.
- β抑制剂与其他治疗方法 (如ACE抑制剂) 一起增强心力衰竭的治疗选择,需要有效地将证据转化为临床实践.
相关概念视频
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...